



Semaglutide

Commercially available as Wegovy® and Ozempic® (by Novo Nordisk). It is an injection given once weekly, and the dosing is titrated, similar to Tirzepatide. In the clinical trial, more than 50% of study subjects lost 15% of body weight and nearly 40% lost 20% of body weight. Common side effects include nausea, vomiting, diarrhea, constipation.

More serious side effects may occur.

Some people should not take Semaglutide. These are people with a personal or close family member with a history of medullary thyroid cancer or multiple endocrine neoplasia (MEN) type I. This is a cancer that has occurred in more than one endocrine gland.